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Abstract
Background: The purpose of this paper is to provide an overview of key aspects of specialised dermatology
nursing practice in the management of patients with moderate to severe atopic dermatitis. The role of
dermatology nurse specialists in supporting patients and promoting disease understanding, education and
treatment adherence continues to evolve. As features of specialised nursing care can also inform other nursing staff
in a wide range of care settings, an overview of key components is examined. Observations presented are from a
pan-European perspective and represent the collected view of a group of dermatology nurse specialists,
dermatologists and patient advocates following two round-table discussions.
Main body: Atopic dermatitis is a common, chronic, inflammatory disease characterised by erythematous/scaling
skin lesions, with often intense pruritus. Disease course is cyclic with periodic disease flares of varying intensity,
presenting management challenges to patients and families. Dermatology nurse specialists play a key role in
providing education and substantial patient support to improve treatment outcomes and quality of life to patients
and their family, delivered within a multidisciplinary team framework. Nurse-led education and 'eczema schools’ are
of benefit in reducing disease severity and improving quality of life by enhancing self-management, adherence and
patient engagement. eHealth tools, such as patient portals or online training platforms, can provide online learning,
individualised education, and help to improve engagement. These and other initiatives, such as written action
plans, are all essential to improve or maintain treatment adherence, self-management and quality of life.
Conclusions: Dermatology nurse specialists play a central role in the assessment and management of moderate to
severe atopic dermatitis patients and families. This places them in an ideal position to build strong and often long-
term relationships with patients and parents. Such engagement promotes trust, assists in setting realistic
expectations of treatment and outcomes, and enhances self-management and engagement in their own care.
Providing emotional support, as well as formal and systematic education (including individualised practical advice)
all contribute to improved treatment adherence and can enhance the quality of life of patients and their families
throughout the course of this long-term condition.
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Background
The purpose of this article is to provide a contemporary
overview of the key aspects of specialised dermatology
nursing practice in patients with atopic dermatitis (AD)
– also known as atopic eczema – and in particular to
examine the evolving role of dermatology nurse special-
ists in supporting patients and promoting disease under-
standing, education and treatment adherence in those
living with moderate to severe AD. A range of different
nurse roles exist that may be involved in the care of AD
patients, including general nurses working within
dermatology, registered dermatology nurses, and nurses
with additional training and responsibilities such as
dermatology clinical nurse specialists, advanced nurse
practitioners and nurse consultants. For simplicity in this
manuscript we have used the term ‘dermatology nurse
specialists’ to refer to those nurses with additional ex-
pertise in specialised dermatology nursing care. These
observations are from a pan-European perspective
formed from a group of specialist dermatology nurses
(ED, NM, SR, KJ, SE), a dermatology nurse researcher
(HvO), dermatologists (LDR, CDC) and a patient advo-
cate (TW), who met to develop a consensus on selected
topics of specialised dermatology nurse care in AD.
AD is a chronic, inflammatory skin disease charac-
terised by erythematous and scaling lesions, often with
intense pruritus [1]. Disease pathophysiology is complex,
involving the interplay of genetic, environmental, and
immunological factors. Defects in the epidermal barrier,
often associated with gene mutations and polymor-
phisms in filaggrin and altered lipid metabolism, contrib-
ute to epidermal dehydration. This predisposes to
immune responses to allergens, skin irritants and micro-
bial proteins with subsequent acute and then chronic cu-
taneous inflammation. AD is common, affecting 20–30%
of children, with most patients developing symptoms in
infancy or early childhood. While most children will
have spontaneous remission, persistence into adulthood
is seen in approximately 30% of cases. The overall preva-
lence of AD in adults is between 2 and 8% and although
adult-onset AD is well recognised, most have had symp-
toms since childhood [2–5]. In 80% of patients, an atopic
background exists (“extrinsic/allergic AD”) with the re-
mainder being non-allergic individuals (i.e., those with
“intrinsic AD”) [6]. Patients with extrinsic AD are at
higher risk of contracting other atopic diseases (allergic
asthma, allergic rhino-conjunctivitis, and food allergy).
Indeed, childhood onset AD is often a forerunner to the
development of one or more atopic conditions in later
life – the so called “atopic march” [7]. Other co-
morbidities are also more common in AD patients.
These include cardiovascular diseases, autoimmune dis-
eases, low mood and issues with self-esteem [8, 9]. Psy-
chological upset and sleep disturbance associated with
skin irritation and pruritus have a substantial impact on
quality of life (QoL) [10–13].
Typically, the disease course is cyclic with periodic ex-
acerbations/disease flares of varying intensity [2]. The
chronic relapsing disease pattern presents challenges for
management, which involves ongoing treatment and
monitoring for therapeutic response and tolerability.
Treatment aims are to alleviate disease symptoms and
reduce the frequency and severity of disease flares/exac-
erbations, to enhance QoL [14, 15]. A detailed summary
of contemporary management approaches is beyond the
scope of the present paper; for further detail on diagno-
sis and treatment, readers are encouraged to review key
clinical guidelines and recommendations [3, 4, 14–17]
and recent informative reviews [1, 2, 18]. Presented here
are the most salient aspects which guide the role of spe-
cialised dermatology nursing care in the effective sup-
port of patients with AD.
Main text
Role of the nurse in the patient-centered care team
AD disease management may be delivered in different
health settings (primary care, day-clinics, and secondary/
tertiary care). The majority of patients have mild disease
and are often managed in the primary care/community
setting; only up to 10% are considered to have severe
disease [14]. Specialist-led care is primarily delivered on
an out-patient or day-clinic basis. Hospital admission for
treatment is less common, although it may be provided
for patients with severe or recalcitrant disease. In cases
where a structured treatment and education program is
considered necessary, in-patient care can help optimise
topical therapy with out-patient follow-up, thereby redu-
cing the need for systemic immunosuppressive or bio-
logic therapy [16].
Nurses in all settings play a vital and valued role in
providing care for the patient with AD [17, 18] (Fig. 1).
Involvement of dermatology nurse specialists in provid-
ing and supporting clinical care allows the dermatologist
to dedicate greater time to clinical aspects of patient
consultations. The nurse –patient consultation addresses
a range of aspects such as disease assessment, structured
education and emotional support. However, no standar-
dised format for consultations currently exists, nor con-
sensus on what key elements should be included. On an
individual patient basis, this may be informed by obser-
vations derived from multidisciplinary team discussions.
A standardised nurse consultation ‘tool’ could be valu-
able as a framework to ensure that all appropriate rele-
vant items are addressed and could allow a more
consistent approach to monitoring disease course and
patient support.
Ideally, moderate to severe AD care is delivered within
a multidisciplinary team, with the focus on delivering
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person-centered care. In this integrated approach, com-
munication, education, and treatment need to be indivi-
dualised to suit the patient’s needs within a shared
decision-making process. This must take into consider-
ation personal disease history, severity and co-
morbidities, and match realistic care expectations and
personal preferences to the best scientific evidence avail-
able. Shared decision making can be supported by pa-
tient decision aids [19].
While the composition of the team varies between set-
tings, institutions and across countries, dermatologists,
dermatology nurse specialists, other nursing staff, pharma-
cists, along with psychologist or psychiatrist support, dieti-
cians and other staff, all play a role [20]. Multidisciplinary
initiatives and interventions, including education about
the condition and its management, as well as psycho-
logical and behavioural programmes, may have a positive
effect on outcomes in moderate to severe AD [21, 22].
Within such a team, nurses often serve as the prin-
cipal contact between the patient (and their family)
and the lead physician and other team members to
support continuity of care [23]. Nurses tend to have
well-established patient rapport and empathy skills,
especially when addressing practical problems in ec-
zema management, and are highly valued by patients
[24]. They are, therefore ideally placed for continuity
of primary patient contact at every stage of care
provision, to both develop and document the patient’s
clinical profile at the initial consultation and engage
with patients through education and training through-
out their care. In addition, dermatology nurse special-
ists may provide education and training to fellow
healthcare workers, both within the team and in other
settings, such as in primary care. Many are also ac-
tively involved in clinical research, integrated with
clinical care.
Establishing and managing realistic patient expecta-
tions in their treatment and their role in self-
management is fundamental. These may vary greatly in
patients (and the parents of children) as may engage-
ment in the shared decision-making process. Some par-
ents/patients are highly motivated and informed, while
others are more reluctant or cautious when seeking in-
formation and receiving appropriate clinical manage-
ment; some may rely completely upon guidance from
the healthcare team. Initial attitudes may change during
the clinical disease course, and with patient experience
and age. Providing patients/parents with the most appro-
priate and realistic information on their disease status,
including the efficacy, safety, and suitability of proposed
treatments, based upon their individual needs at each
stage of the disease, is vital. Such information should be
delivered in a clear, consistent fashion by all members of
the healthcare team to inspire confidence and minimise
Fig. 1 Overview of the role of dermatology nurse specialist in atopic dermatitis care
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confusion or misunderstanding on the part of the patient
or parent [14, 15, 25–28].
Active engagement of the patient in decision mak-
ing is paramount. A genuine sense of personal re-
sponsibility should be encouraged – especially
regarding the importance of treatment adherence in
achieving optimal self-management and optimal out-
comes [19]. For example, while skincare and applica-
tion of topical therapies is time consuming, and
patient dissatisfaction contributes to poor treatment
adherence, this may be overcome with support and
education. Even with good understanding and accept-
ance of the chronic relapsing nature of moderate to
severe AD, patients will naturally experience disap-
pointment during adverse changes in their condition
and nurses can offer reassurance and hope. Nurses
can guide patients adapt through the disease cycle
and therapy changes. Patients should be informed and
understand that treatment escalation may be an ef-
fective and necessary strategy that is often only
needed as a temporary measure to control disease ex-
acerbations. Correct management of the medication,
including frequency of administration and adaptation
of the potency of the drugs/ointments, is crucial.
Greater understanding will improve the patient’s ad-
herence and therefore, enhance the clinical outcome.
Overview of clinical management
Diagnosis of AD is based on family and personal his-
tory and clinical features. Most diagnostic criteria
consider cutaneous aspects (including dry skin ± ery-
thema, induration, and scaling), pruritus and a per-
sonal or family history of allergic skin or respiratory
disease (i.e., AD, asthma or allergic rhino-
conjunctivitis) as major diagnostic criteria, with dis-
ease chronicity and/or a relapsing pattern, and early
onset (< 2 years of age) supportive of a diagnosis [29,
30]. Identification of additional trigger factors (food,
environmental and job-related factors) is crucial in
disease management. Establishing a complete profile
of the patient is indispensable to determine the thera-
peutic strategy. Dermatology nurse specialists are
often involved in skilled clinical assessment, gathering
data to inform the diagnostic process and the estima-
tion of disease severity and QoL impact.
Most treatment recommendations are based on dis-
ease severity and therapeutic response; a framework
for categorizing AD severity as mild, moderate, or se-
vere is important to understand and anticipate an in-
dividual’s treatment needs [14, 15, 25]. While
treatment decisions can be complex, in part due to
the wide variety of topical and systemic therapies
available, most evidence-based clinical practice guide-
lines from specialist bodies in Europe and the US
provide treatment recommendations on the basis of dis-
ease severity and treatment response [14, 15, 25–28].
Since AD is characterised by exacerbation and disease
flares, followed by remission, severity should be assessed
both at presentation and throughout the disease course;
sequential measurements are ideal to generate reliable
estimates [26]. A wide range of validated disease scoring
tools are available, such as the Scoring Atopic Dermatitis
Index (SCORAD) – with clinical and patient-oriented
versions (PO-SCORAD), each assessing the extent and
severity of skin involvement and also a subjective assess-
ment of the severity of pruritus and sleep disturbance
[31–33]. The Eczema Area and Severity Index (EASI) as-
sesses the extent and severity of skin disease only [32].
Patient-reported outcome measures (PROMs) are also
used for assessing symptoms or impact on QoL. These
may be disease-specific – such as the validated Patient-
Oriented Eczema Measure (POEM) and more generic
dermatology-focused tools such as the Dermatology Life
Quality Index (DLQI) [34–36]. Although these tools
may not always be employed in the clinical practice set-
ting, their use is on the increase and, by using them,
nurses can contribute to the objective assessment to in-
form disease management and decisions about treatment
and its evaluation. Discussing these measures with pa-
tients is often useful to provide context and help them
gain a better understanding of their disease and its
impact.
Treatment aspects
The principles of treatment for moderate to severe AD
are four-fold; (1) identification and avoidance of trigger
factors; (2) skin rehydration to repair/restore the im-
paired skin barrier; (3) reducing itching/pruritus; (4) re-
ducing skin inflammation, especially during disease
flares, via topical and systemic therapies. Dermatology
nurse specialists provide a crucial resource for patient
education and support in all aspects of treatment.
Environmental irritants and known allergens can ag-
gravate affected skin of AD patients and promote disease
flares [14]. Well-recognised irritants include fabrics such
as acrylic or wool, household chemicals (bleach or sol-
vents), and fragrances. Daily use of emollients to reduce
moisture loss is the mainstay of treatment. This has been
shown to reduce pruritus and may also have a steroid-
sparing effect, reducing the amount of topical corticoste-
roids (TCS) required [14, 37–39]. Specific skincare prod-
ucts such as emollients should be recommended, and
according to personal needs lotions, creams or oint-
ments that are preferred by the patient. Most over-the-
counter products seem to be as effective as specialist
prescription formulations [14]. Dermatology nurse spe-
cialists trained in AD management have a good know-
ledge of available products and are skilled in providing
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advice to patients who have difficulty in finding an emol-
lient regime that suits their individual needs and
preferences.
Key factors determining emollient use are the level of
dryness of the skin and patient preference (i.e., one they
are most likely to use). As individual preference is im-
portant to promote adherence [40]; it may be necessary
to trial a range of products to establish a preferred com-
bination of products. In principle, emollients should be
applied directly on the skin after bathing and then ap-
plied on 2–3 further occasions throughout the day. Iden-
tifying the appropriate skincare regimen may take time,
and once established, its use in everyday life may be
time-consuming, and these aspects may be a source of
patient or parental concern.
Wet-wrap therapy is a useful adjunct to standard skin-
care and topical therapies [41–44]. Their clinical value has
been highlighted in Nicol’s robust large nurse-led study
[41], although recent systematic review evidence calls for
further research [42]. Wet wrapping involves the applica-
tion of emollients or TCS, which are then covered by a
layer of wet bandages or clothing and then by a further
layer of dry clothing. Wet-wraps are especially useful in
children as they provide a barrier to scratching affected
skin in acute flares (although they are contraindicated
when eczema is infected) [41–44]. A principal drawback is
poor adherence, chiefly due to inadequate patient educa-
tion. Nurse support in wet-wrap technique through dem-
onstration is especially helpful, and particularly so for
children, where engagement of both parent and child can
be enhanced by incorporation of wet-wrapping into their
lifestyle. Play strategies, such as “reward stickers” or wet-
wrapping a favourite doll, can increase the acceptability of
this technique to the child.
Medical therapies include topical agents, in particular
TCS or topical calcineurin inhibitors (TCIs), photother-
apy and systemic or biologic agents (immunosuppres-
sants or biologic therapies e.g. dupilumab). Evidence-
based guidelines recommend a stepwise approach to
agent selection with a range of topical agents being con-
sidered as first-line before systemic immunosuppressants
or biologic therapies are considered [14, 15, 25–28]
(Fig. 2).
In general, the therapeutic approach is initial use of
medium potency or higher-dose TCS preparations prior
to TCIs. In severe AD, initial use of higher potency TCS
may be preferred. When used appropriately TCS are
safe; local side effects with longer-term use are uncom-
mon and systemic side effects are rare. Nevertheless,
safety may be an important aspect of patients often un-
due concerns or overt ‘steroid phobia’, especially in par-
ents of affected children, which contributes to reduced
treatment adherence. Explanation of the benefits and
risks are, therefore, key aspects of patient education and
reassurance [45, 46].
Dermatology nurse specialists are actively involved in
delivering phototherapy to patients using established
protocols, although treatment may be time-consuming
for patients (and their families). Phototherapy is usually
given in schedules of 3–5 weekly treatments for 6–12
weeks, with discontinuation if little response is seen
within 2 months [14]. Treatment with existing care
Fig. 2 Overview of treatment principles in atopic dermatitis. Skin-care is essential and should be maintained regardless of any additional
treatment. Topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) are first-line therapies. A wide range of TCS preparations are
available, and choice (potency, strength, dosage) should be tailored towards individual patient needs; typically, medium- to high-potency TCSs
are used for short periods to treat acute flares. In sensitive areas (e.g. face, neck, flexural areas) lower-potency TCS or TCIs are recommended.
*Systemic immunosuppressant therapy includes cyclosporine A (licensed therapy in Europe / off-label in the US) azathioprine, methotrexate,
mycophenolate mofetil (all off-label) and systemic corticosteroids. †Biologic therapies e.g., dupilumab, now approved in Europe and the US in
refractory patients with moderate-to-severe AD, either as monotherapy or in combination with TCS. Information based on published
recommendations [3, 4, 14–17]
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(emollients ± TCS) should be continued to minimise risk
of acute flares. However, access to established centres
may limit the utility of phototherapy to patients with
moderate to severe AD who may benefit [14].
Patients with moderate-to severe AD may require sys-
temic therapy with immunosuppressants (cyclosporine A,
azathioprine, methotrexate, and mycophenolate mofetil)
or targeted biologics such as dupilumab. Whilst decision-
making should be shared between the patient and the
physician to take account of patient preference, screening
for the suitability of immunosuppressants or biologics,
along with monitoring for adverse effects and clinical re-
sponses, are often coordinated by dermatology nurse spe-
cialists [15]. This may involve the ordering and review of
various blood investigations according to local guidelines
and protocols, and dermatology nurse specialists are in-
creasingly involved in monitoring patients on therapies.
When stepping-up treatment to systemic or biologic ther-
apies, comprehensive discussions with patients or their
family may be required to explain the rationale for such
treatment and how duration of systemic treatment would
be guided by clinical response and tolerability. Education
on the more common side-effects of immunosuppressants
or biologics and to provide perspective on the risk-benefit
profile of specific agents is also important to raise aware-
ness and reassure patients and their family. In addition,
many of these agents may be given as subcutaneous injec-
tion (azathioprine, methotrexate, dupilumab) and while in
some circumstances nurse-administration will be pre-
ferred, self-administration is a more practical option. As
such, education and training in self-injection is essential.
Promoting wellbeing
Patients with moderate to severe AD are at an increased
risk of a wide range of co-morbidities, including cardiovas-
cular, autoimmune, and psychiatric diseases [8, 9]. The sys-
temic impact of AD is such that it has been considered by
many – similar to psoriasis – to be a systemic disease [47].
An essential aspect of holistic, integrated care is the promo-
tion of healthier lifestyles and supporting adherence with
recommended medical care. This is important at all ages.
For example, children with AD should be vaccinated in line
with local or national vaccination schedules, although
where possible, vaccines should be avoided during acute
flares [14]. Healthy lifestyle changes may be required for
some adult AD patients with moderate to severe disease [8,
9]. When appropriate, efforts to reduce alcohol use (and to-
bacco cessation) and promote weight-loss, with develop-
ment of a regular exercise regime may all be important
aspects of holistic patient care to improve wellbeing [9].
Other important aspects of wellbeing include the iden-
tification of those patients with a psychological disturb-
ance. It should be recognised that adverse mood and
poorer QoL can also develop in families of patients with
moderate to severe AD. These may be formally mea-
sured and monitored by appropriate validated measures
(e.g., Hospital Anxiety and Depression Scale) [48], al-
though other factors beyond overt depression can be a
particular burden. An important judgement is the need
to assess when to instigate specialist referral to psychi-
atric or clinical psychology services.
Although beyond the scope of this article, a range of
factors may adversely impact the patient’s sense of well-
being. Sleep disturbance, self-esteem and social anxiety,
intimate personal relationships and financial concerns
due to treatment costs and impact upon work productiv-
ity and absences, can each contribute to lower mood
and poorer disease-related life quality. Anxiety fre-
quently relates to poor adherence to therapies, which
may itself be associated with factors such as steroid aver-
sion [49]. Nurses are well placed to provide counselling
to patients and parents, actively listen; they may also use
motivational interviewing to help minimise these im-
pacts and support better adherence.
Patient education
Nurses play a key role in the development and provision
of systematic education on AD, both to patients, their
relatives, and the wider healthcare community, on dis-
ease background, standards of care, and detailing risks
and benefits of the available recommended treatments.
In most therapeutic patient education (TPE) pro-
grammes, nurses often play a primary role in providing
evidence-based and often individualised information to
support self-management and promote active participa-
tion in shared decision making [20, 50–54]. Educational
needs that are required to support self-care varies be-
tween patients, and needs-assessment can be difficult;
simple scoring tools have been developed for this pur-
pose [55]. While such education should be universal it is
of particular importance in those patients with recalci-
trant or refractory disease, or where treatment adher-
ence or treatment concerns exist, and for those patients
or families with poorer QoL, or who require additional
psychological support [50, 52].
Two main service delivery models for education deliv-
ery exist; nurse-led focused group education and a
broader multidisciplinary “eczema school” approach [50,
56]. To date, most experience and evaluation of the ben-
efits of education is in children, where education may be
directed towards children and their parents. There is no
strong evidence that either approach is more effective as
no direct comparative studies have been conducted. A
recent Cochrane review of educational interventions in
children concluded that either approach may lead to im-
provements in disease severity and QoL [56], although
the eczema school approach is much more resource in-
tensive. The “eczema school approach” was pioneered in
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Europe and has now also been used in the US with some
success [57]. Eczema schools provide a structured inter-
vention program for patients or parents of children with
AD. Educational components include: disease informa-
tion, practical advice on skin care and avoidance strat-
egies, and nutritional advice. Psychological and social
support are also provided. In the UK, nurse-led educa-
tion such as the Eczema Education Programme (EEP) in-
volving group education and social learning, has also
been well received by parents and preliminary evidence
indicates its clinical and QoL benefits [17, 58, 59], al-
though further evaluative trial evidence is required. Al-
though time-consuming, individualised education within
an out-patient or day-clinic, may be more appropriate
when delivering specific patient training on skincare and
the use of topical therapies in adult patients with more
complex educational needs.
Patients with moderate to severe AD may suffer a
sense of isolation and learning about fellow patients’ ex-
periences can help to alleviate this. The DIPEx (personal
experiences of health and illness) international collabor-
ation is a useful resource, providing videos of patient in-
terviews on a wide range of medical conditions to
provide genuine insight into the experiences of patients,
family, and carers [60–62]. While patients should be en-
couraged to learn about their condition independently, −
and the internet is a valuable source of information for
some patients, − misleading or adverse impressions of
appropriate therapy for moderate to severe AD can be
made [63]. Nurses can provide guidance on appropriate
reliable evidence-based information sources.
eHealth strategies for management
Electronic digital health services (eHealth) – the use of
information and communication technologies for health
[64] – provide an important additional avenue to sup-
port AD care [65, 66]. In addition to assisting in sched-
uling appointments and prescription reminders, eHealth
offers the ability to provide online medical consultations,
with different studies reporting equivalent improvements
in AD outcomes and QoL with online follow-up ap-
pointments compared with conventional face-to-face
consultations [67–69].
eHealth strategies are considered favourably by both
healthcare workers and patients, and nurses are an im-
portant contact in supporting access to eHealth re-
sources. Such resources can range from static tools
(providing core disease information) to more dynamic
ones providing interactive online learning, self-
management training or a personal ePortal providing
patient-specific access to their electronic health records
[70]. Mobile apps are available to monitor disease sever-
ity or symptoms such as itch [71, 72], and it is likely that
the use of such tools by patients will increase.
Providing a suite of tools such as these can deliver
individualised education and engagement [73, 74]. In-
creasingly, such tools are being developed and shared by
national bodies or dedicated institutions e.g., those de-
veloped by the University Medical Center of Utrecht in
the Netherlands or by the Foundation for Atopic
Dermatitis [75, 76] In the US, the American College of
Allergy, Asthma & Immunology, in partnership with the
Allergy & Asthma Network patient organization, have
developed an interactive tool to support patients with
moderate-to-severe AD in shared decision making with
their physician during a clinical consultation [77].
The educational and eHealth strategies described
above can inform and support adherence. The chronic
relapsing disease course, which requires rigorous atten-
tion to skincare, and different treatments over a pro-
longed period, can translate into a complex management
plan, with episodes of disappointment and frustration re-
garding outcomes with topical therapies. This can result
in reduced levels of adherence and subsequently poorer
outcomes in moderate to severe AD.
The use of written eczema action plans, which provide
patients or parents with a checklist of instructions, are
also valuable to support self-management. Plans such as
these are already an established aspect of asthma care,
and although data on their effectiveness in AD is limited,
they would seem to provide an important aspect to sup-
porting care in AD and patient engagement [78–80]. Ac-
tion plans for AD have been developed by a number of
professional organizations, including the American
Academy of Dermatology [81].
Conclusions
Dermatology nurse specialists are key players in the as-
sessment and management of patients with moderate to
severe AD. Their central role within a multidisciplinary
team places them in an ideal position to build strong
and often long-term relationships with patients and par-
ents. Such engagement promotes trust, assists in setting
realistic expectations of treatment and outcomes, and
enhances self-management and engagement in their own
care. Providing emotional support, as well as formal and
systematic education and individualised practical advice,
may contributes to improved treatment adherence and
can enhance QoL of patients and their families through-
out the course of this chronic disease. The aspects de-
scribed in this review may have value in educating non-
specialist nursing staff in the evolving role of dermatol-
ogy nurse specialists in moderate to severe AD patient
management and holistic care.
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